As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
REGULATORY
Yescarta, Breyanzi Clear Panel Review for Second-Line Use
A health ministry panel on December 12 gave the thumbs-up to the label expansions of two CAR-T cell therapies - Daiichi Sankyo’s Yescarta (axicabtagene ciloleucel) and Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) - to allow their use in the earlier-lines…
To read the full story
Related Article
- Yescarta Gets Second-Line Nod for Large B-Cell Lymphoma in Japan
December 26, 2022
- Breyanzi Now Approved in Japan for 2nd-Line Large B-Cell Lymphoma: BMS
December 21, 2022
REGULATORY
- Deregulation Panel Urges Discussions on Secondary Use of Medical Data Without Patient Consent
June 2, 2023
- Public Knowledge-Based Application OK’ed for Endoxan Label Expansion
June 2, 2023
- SaMD Could Be Eligible for 2-Stage Approval System: MHLW
June 1, 2023
- Japan Diet Enacts Bill to Create “Japan CDC”
June 1, 2023
- Japan to Quadruple Supplies of Sublingual Hay Fever Therapy in 5 Years
May 31, 2023
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…